

U.S. 09/778,187

Docket No. 2873-US-CIP

3. Remarks

Claims 20-34 are pending in the application with claims 20 and 22 being in independent form. Claims 1-19 and 35-63 are cancelled. Applicants reserve the right to pursue this subject matter in other related applications and have not surrendered any rights to this subject matter.


Claims 20 and 21 have been cancelled without prejudice. Applicants reserve the right to pursue this subject matter in other related applications and have not surrendered any rights to this subject matter.

Claims 22, 23, and 26 have been amended to delete reference to fragments. Applicants reserve the right to pursue this subject matter in other related applications and have not surrendered any rights to this subject matter.

Claims 24, 25, 27, and 28 have been amended to specify the first and last amino acids of the claimed polypeptide. No new matter has been added.

Applicants believe all issues have been addressed and kindly request reconsideration and allowance of the claims. If any outstanding issues remain that may be easily reconciled, the Examiner is invited to telephone Applicants' representative at the number provided below.

Respectfully submitted,



James E. Klaniecki
Attorney for Applicants
Registration No. 38,207
Direct Dial: 206-265-7145

Please send all further correspondence to:

22932

Immunex Corporation
1201 Amgen Court West
Seattle, WA 98119-3105
Telephone (206) 265-7000